Ceftobiprole (Synonyms: 头孢吡普; Ro 63-9141; BAL 9141)

目录号: HY-112579 纯度: 96.44%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Ceftobiprole (Ro 63-9141) 是一种广谱头孢菌素，对甲氧西林 (MRSA)、耐万古霉素葡萄球菌 (VRSA) 和耐青霉素链球菌具有高水平的体外活性，对 MRSA 的 MIC₉₀ 值为 2 μg/mL。Ceftobiprole 还抑制革兰氏阳性和革兰氏阴性病原体。Ceftobiprole 可用于医院获得性肺炎（不包括呼吸机相关性肺炎）和社区获得性肺炎的研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Ceftobiprole Chemical Structure

CAS No. : 209467-52-7

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
1 mg	￥1200	In-stock
5 mg	￥3100	In-stock
10 mg	￥4500	In-stock
25 mg	现货	询价
50 mg	现货	询价
100 mg		询价
200 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

MCE 顾客使用本产品发表的 2 篇科研文献

Ceftobiprole 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Antibiotic 亚型特异性产品:

查看所有亚型

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

生物活性
纯度 & 产品资料
参考文献

生物活性

Ceftobiprole (Ro 63-9141) is a broad-spectrum cephalosporin with high levels of in vitro activity against methicillin- (MRSA) and vancomycin-resistant staphylococci (VRSA) and penicillin-resistant streptococci with a MIC₉₀ value of 2 μg/mL for MRSA. Ceftobiprole also inhibits gram-positive and gram-negative pathogens. Ceftobiprole can be used for the study of hospital-acquired pneumonia (excluding ventilator-associated pneumonia) and community-acquired pneumonia^[1]^[2]^[3].

IC₅₀ & Target

β-lactam

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
THP-1	EC₅₀	0.07 mg/L Compound: BPR	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 25293 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 25293 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs	[PMID: 19289525]
THP-1	EC₅₀	0.07 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus N4042228 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus N4042228 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs	[PMID: 19289525]
THP-1	EC₅₀	0.08 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus N4090440 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus N4090440 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs	[PMID: 19289525]
THP-1	EC₅₀	0.19 mg/L Compound: BPR	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus NRS52 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs Antimicrobial activity against methicillin-susceptible Staphylococcus aureus NRS52 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs	[PMID: 19289525]
THP-1	EC₅₀	0.2 mg/L Compound: BPR	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 25293 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4 Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 25293 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4	[PMID: 19289525]
THP-1	EC₅₀	0.2 mg/L Compound: BPR	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 11632 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4 Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 11632 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4	[PMID: 19289525]
THP-1	EC₅₀	0.2 mg/L Compound: BPR	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus NRS52 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4 Antimicrobial activity against methicillin-susceptible Staphylococcus aureus NRS52 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4	[PMID: 19289525]
THP-1	EC₅₀	0.205 mg/L Compound: BPR	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 11632 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 11632 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs	[PMID: 19289525]
THP-1	EC₅₀	0.23 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired vancomycin-intermediate Staphylococcus aureus NRS126 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs Antimicrobial activity against hospital-acquired vancomycin-intermediate Staphylococcus aureus NRS126 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs	[PMID: 19289525]
THP-1	EC₅₀	0.25 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired vancomycin-resistant Staphylococcus aureus VRS1 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs Antimicrobial activity against hospital-acquired vancomycin-resistant Staphylococcus aureus VRS1 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs	[PMID: 19289525]
THP-1	EC₅₀	0.26 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired vancomycin-intermediate Staphylococcus aureus NRS18 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs Antimicrobial activity against hospital-acquired vancomycin-intermediate Staphylococcus aureus NRS18 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs	[PMID: 19289525]
THP-1	EC₅₀	0.28 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 33591 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 33591 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs	[PMID: 19289525]
THP-1	EC₅₀	0.28 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 33591 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4 Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 33591 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4	[PMID: 19289525]
THP-1	EC₅₀	0.28 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 33592 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4 Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 33592 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4	[PMID: 19289525]
THP-1	EC₅₀	0.28 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 433000 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4 Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 433000 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4	[PMID: 19289525]
THP-1	EC₅₀	0.28 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired vancomycin-intermediate Staphylococcus aureus NRS18 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4 Antimicrobial activity against hospital-acquired vancomycin-intermediate Staphylococcus aureus NRS18 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4	[PMID: 19289525]
THP-1	EC₅₀	0.28 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired vancomycin-intermediate Staphylococcus aureus NRS126 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4 Antimicrobial activity against hospital-acquired vancomycin-intermediate Staphylococcus aureus NRS126 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4	[PMID: 19289525]
THP-1	EC₅₀	0.28 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired vancomycin-resistant Staphylococcus aureus VRS1 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4 Antimicrobial activity against hospital-acquired vancomycin-resistant Staphylococcus aureus VRS1 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4	[PMID: 19289525]
THP-1	EC₅₀	0.33 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus NRS192 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4 Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus NRS192 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4	[PMID: 19289525]
THP-1	EC₅₀	0.33 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus N4090440 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4 Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus N4090440 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4	[PMID: 19289525]
THP-1	EC₅₀	0.33 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus N4042228 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4 Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus N4042228 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4	[PMID: 19289525]
THP-1	EC₅₀	0.33 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus STA 44 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4 Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus STA 44 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4	[PMID: 19289525]
THP-1	EC₅₀	0.33 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus STA 228 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4 Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus STA 228 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4	[PMID: 19289525]
THP-1	EC₅₀	0.33 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus isolate MEH2225605 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4 Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus isolate MEH2225605 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 7.4	[PMID: 19289525]
THP-1	EC₅₀	0.41 mg/L Compound: BPR	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 25293 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5 Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 25293 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5	[PMID: 19289525]
THP-1	EC₅₀	0.41 mg/L Compound: BPR	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 11632 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5 Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 11632 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5	[PMID: 19289525]
THP-1	EC₅₀	0.41 mg/L Compound: BPR	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus NRS52 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5 Antimicrobial activity against methicillin-susceptible Staphylococcus aureus NRS52 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5	[PMID: 19289525]
THP-1	EC₅₀	0.54 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus NRS192 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5 Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus NRS192 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5	[PMID: 19289525]
THP-1	EC₅₀	0.54 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus N4090440 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5 Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus N4090440 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5	[PMID: 19289525]
THP-1	EC₅₀	0.54 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus N4042228 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5 Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus N4042228 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5	[PMID: 19289525]
THP-1	EC₅₀	0.54 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus STA 44 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5 Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus STA 44 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5	[PMID: 19289525]
THP-1	EC₅₀	0.54 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus STA 228 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5 Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus STA 228 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5	[PMID: 19289525]
THP-1	EC₅₀	0.54 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus isolate MEH2225605 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5 Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus isolate MEH2225605 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5	[PMID: 19289525]
THP-1	EC₅₀	0.7 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus NRS192 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus NRS192 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs	[PMID: 19289525]
THP-1	EC₅₀	0.73 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 433000 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 433000 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs	[PMID: 19289525]
THP-1	EC₅₀	0.77 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired vancomycin-intermediate Staphylococcus aureus NRS126 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5 Antimicrobial activity against hospital-acquired vancomycin-intermediate Staphylococcus aureus NRS126 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5	[PMID: 19289525]
THP-1	EC₅₀	0.77 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired vancomycin-resistant Staphylococcus aureus VRS1 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5 Antimicrobial activity against hospital-acquired vancomycin-resistant Staphylococcus aureus VRS1 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5	[PMID: 19289525]
THP-1	EC₅₀	0.77 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 33591 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5 Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 33591 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5	[PMID: 19289525]
THP-1	EC₅₀	0.77 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 33592 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5 Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 33592 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5	[PMID: 19289525]
THP-1	EC₅₀	0.77 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 433000 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5 Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 433000 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5	[PMID: 19289525]
THP-1	EC₅₀	0.77 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired vancomycin-intermediate Staphylococcus aureus NRS18 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5 Antimicrobial activity against hospital-acquired vancomycin-intermediate Staphylococcus aureus NRS18 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs at pH 5.5	[PMID: 19289525]
THP-1	EC₅₀	0.82 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus isolate MEH2225605 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus isolate MEH2225605 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs	[PMID: 19289525]
THP-1	EC₅₀	0.88 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus STA 228 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus STA 228 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs	[PMID: 19289525]
THP-1	EC₅₀	0.94 mg/L Compound: BPR	Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus STA 44 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs Antimicrobial activity against Panton-valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus STA 44 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs	[PMID: 19289525]
THP-1	EC₅₀	1.23 mg/L Compound: BPR	Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 33592 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus ATCC 33592 infected in human THP-1 cells assessed as change in bacterial count after 24 hrs	[PMID: 19289525]

体外研究
(In Vitro)

Ceftobiprole (Ro 63-9141) has demonstrates activity against important gram-positive bacteria, including S. pneumonia (PRSP), Methicillin-resistant S. aureus (MRSA), and E. faecalis with MIC₉₀ values of 0.25, 2, and 2 mcg/mL, respectively. Ceftobiprole has also demonstrated potent in vitro activity against several clinical isolates of community-associated Methicillin-resistant S. aureus (CA-MRSA), S. aureus (VISA), and S. aureus (VRSA), with a minimum inhibitory concentration (MIC) of 2 mcg/mL^[1].
Ceftobiprole is highly active against S. aureus, withMICs ranging from 0.12 to 4 mg/L (only one resistant strain,MIC of 4 mg/L). Furthermore, Ceftobiprole is twice more active on Methicillin-susceptible S. aureus (MSSA) strains with MIC₅₀ and MIC₉₀ of 0.5 mg/L than on MRSA strains with MIC₅₀ and MIC₉₀ of 1 mg/L. Moreover, Panton-Valentine leukocidin (PVL)+MRSA are slightly more susceptible to Ceftobiprole (MIC₅₀ of 0.5 mg/L and MIC₉₀ of 1 mg/L) than PVL-MRSA (MIC₅₀ and MIC₉₀ of 1 mg/L)^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

534.57

Formula

C₂₀H₂₂N₈O₆S₂

CAS 号

209467-52-7

性状

固体

颜色

Light yellow to yellow

中文名称

头孢吡普；头孢托罗

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years

*该产品在溶液状态不稳定，建议您现用现配，即刻使用。

溶解性数据

细胞实验：

DMSO 中的溶解度 : 4.95 mg/mL (9.26 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.8707 mL	9.3533 mL	18.7066 mL
5 mM	0.3741 mL	1.8707 mL	3.7413 mL
10 mM	---	---	---

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液；该产品在溶液状态不稳定，建议您现用现配，即刻使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.5 mg/mL (0.94 mM); 澄清溶液

此方案可获得 ≥ 0.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 5.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 0.5 mg/mL (0.94 mM); 澄清溶液

此方案可获得 ≥ 0.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 5.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 0.5 mg/mL (0.94 mM); 澄清溶液

此方案可获得 ≥ 0.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 5.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

*该产品在溶液状态不稳定，建议您现用现配，即刻使用。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 96.44%

选择批次：

Data Sheet (636 KB) SDS (393 KB)

COA (201 KB) HNMR (303 KB) RP-HPLC (265 KB) MS (70 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Kisgen J, et al. Ceftobiprole, a Broad-Spectrum Cephalosporin With Activity against Methicillin-Resistant Staphylococcus aureus (MRSA). P T. 2008 Nov;33(11):631-41. [Content Brief]

[2]. Hodille E, et al. In vitro activity of ceftobiprole on 440 Staphylococcus aureus strains isolated from bronchopulmonary infections. Med Mal Infect. 2017 Mar;47(2):152-157. [Content Brief]

[3]. E Azoulay-Dupuis, et al. Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia. Antimicrob Agents Chemother. 2004 Apr;48(4):1105-11. [Content Brief]

Ceftobiprole 相关分类

Inflammation/Immunology Infection

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液；该产品在溶液状态不稳定，建议您现用现配，即刻使用。

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.8707 mL	9.3533 mL	18.7066 mL	46.7666 mL
DMSO	5 mM	0.3741 mL	1.8707 mL	3.7413 mL	9.3533 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

Ceftobiprole (Synonyms: 头孢吡普; Ro 63-9141; BAL 9141)

Customer Review

MCE 顾客使用本产品发表的 2 篇科研文献

Ceftobiprole 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Antibiotic 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Ceftobiprole 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Ceftobiprole (Synonyms: 头孢吡普; Ro 63-9141; BAL 9141)

Customer Review

Ceftobiprole 相关抗体

MCE 顾客使用本产品发表的 2 篇科研文献

Ceftobiprole 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Antibiotic 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

Ceftobiprole 相关抗体:

摩尔计算器

稀释计算器

Ceftobiprole 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z